Moffitt Cancer Center researchers, led by cancer biologist Eric Lau, demonstrated how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase tumor infiltrating lymphocytes, promote antitumor immunity, and improve the efficacy of immunotherapy.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
